Mirae Asset Global Etfs Holdings Ltd. Fate Therapeutics Inc Transaction History
Mirae Asset Global Etfs Holdings Ltd.
- $47.1 Billion
- Q2 2025
A detailed history of Mirae Asset Global Etfs Holdings Ltd. transactions in Fate Therapeutics Inc stock. As of the latest transaction made, Mirae Asset Global Etfs Holdings Ltd. holds 57,321 shares of FATE stock, worth $69,358. This represents 0.0% of its overall portfolio holdings.
Number of Shares
57,321
Previous 59,861
4.24%
Holding current value
$69,358
Previous $47,000
36.17%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding FATE
# of Institutions
150Shares Held
83.4MCall Options Held
179KPut Options Held
13.4K-
Redmile Group, LLC San Francisco, CA12.9MShares$15.6 Million1.75% of portfolio
-
Black Rock Inc. New York, NY10.1MShares$12.2 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.77MShares$10.6 Million0.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il4.54MShares$5.5 Million0.0% of portfolio
-
Jpmorgan Chase & CO New York, NY3.4MShares$4.11 Million0.0% of portfolio
About FATE THERAPEUTICS INC
- Ticker FATE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 97,000,304
- Market Cap $117M
- Description
- Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...